Lundbeck's antipsychotic Serdolect safe for some patients, US panel says
This article was originally published in Scrip
Lundbeck's atypical antipsychotic Serdolect (sertindole) could be safely used by some schizophrenia patients but is not safe for broad treatment owing to cardiac risks, a US FDA advisory panel has said.
You may also be interested in...
Providing information in a pre-IND meeting request will facilitate a more efficient development process, agency says in a new guidance; generally, there is insufficient information to assess if and when an emergency use authorization might be appropriate when a sponsor first enters discussions with the FDA.
CDER wants sponsors to use the NextGen Portal for electronic submission of promotional pieces to the Office of Prescription Drug Promotion, rather than sending in paper or physical media such as CDs; availability of this alternative pathway does not affect requirement for eCTD submission of some types of promotional materials starting in June 2021.
US FDA research finds consumer attitudes are more positive when animated characters personify drug benefits or sufferers, rather than representing the disease itself; OPDP staff also present research on consumer understanding of oncology endpoints and prescribers’ ability to detect deceptive ads.